Claims

1. The use of a gaseous mixture containing xenon gas and nitrous oxide gas to manufacture all or part of an inhalable medicament for preventing or treating a neurointoxication in man, the volume proportion of xenon being between 5% and 45% and the volume proportion of nitrous oxide being between 10% and 50%.

2. The use as claimed in claim 1, characterized in that the neurointoxication results from a cerebral excess of one or more neurotransmitters.

3. The use as claimed in either of claims 1 and 2, characterized in that the mixture containing xenon and nitrous oxide acts on at least one cerebral receptor so as to reduce the release and/or the effects of dopamine, glutamate, serotonin, taurine, GABA, noradrenalin and/or any other neurotransmitter.

4. The use as claimed in one of claims 1 to 3, characterized in that the remainder of the gaseous mixture is oxygen.

5. The use as claimed in one of claims 1 to 4, characterized in that the volume proportion of xenon is between 20% and 40% and the volume proportion of nitrous oxide is between 10% and 40%.

6. The use as claimed in one of claims 1 to 5, characterized in that the volume proportion of xenon is between 20% and 32% and the volume proportion of nitrous oxide is between 20% and 40%, and preferably the volume proportions of xenon and of nitrous oxide are each about 30%.

7. The use as claimed in one of claims 1 to 4, characterized in that the volume proportion of xenon is between 10% and 20% and the volume proportion of nitrous oxide is between 40% and 50%, and preferably the volume proportion of xenon is about 16% and the volume proportion of nitrous oxide is about 50%.

8. The use as claimed in one of claims 1 to 7, characterized in that the medicament also contains oxygen, an oxygen/nitrogen mixture or air, and the gaseous mixture preferably consists of xenon and nitrous oxide, the remainder being oxygen.

9. The use as claimed in one of claims 1 to 8, characterized in that the medicament is ready-to-use.

10. The use as claimed in one of claims 1 to 9, characterized in that the neurointoxication is of the type giving rise to a state of addiction.

11. A gaseous mixture containing from 5% to 35% by volume of xenon and from 10% to 50% by volume of nitrous oxide, as an inhalable medicament.

12. The gaseous mixture as claimed in claim 11, characterized in that it also contains oxygen.

13. The mixture as claimed in either of claims 11 and 12, characterized in that it consists of from 20% to 32% by volume of xenon and from 20% to 40% of nitrous oxide, the remainder being oxygen.

14. The mixture as claimed in one of claims 10 to 13, characterized in that the volume proportions of xenon and of nitrous oxide are each about 30%.

15. The mixture as claimed in one of claims 11 to 13, characterized in that it consists of from 10% to 20% by volume of xenon and from 45% to 50% of nitrous oxide, the remainder being oxygen, and preferably the volume proportion of xenon is about 16% and the volume proportion of nitrous oxide is about 50%.